FL-KNOWBE4
29.3.2023 14:01:30 CEST | Business Wire | Press release
KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, released a new report showing the continued impact cyber crime is having on state and local governments entitled “The Economic Impact of Cyber Attacks on Municipalities”.
KnowBe4’s report details the financial costs, reputational effects, level of public trust and other impact cyber attacks have on municipalities. The report breaks down the impact cyber attacks have into five target areas: the average financial loss from state and local governments, the denial of service to citizens due to financial loss, the frequency/types of attacks and the risk of recurring attacks, the challenge of allocating capital to prevent attacks and the decline of economic investment in municipalities.
Additionally, the new reports revealed ransomware continues to plague municipalities in all industry sectors. Business email compromise (BEC) attacks were also proven to be one of the most lucrative forms of cyber attacks in 2022, generating billions of dollars lost across all sectors and increasing across all sectors by 175%, with an 81% surge in 2022. State and local governments are particularly vulnerable to these attacks due to government transparency laws which allow cyber criminals to more easily tailor their attack to the victim.
Key findings from the report include:
- Many municipality cybersecurity budgets are underfunded or do not exist at all. According to the National Association of State Chief Information Officers (NASCIO), most state cybersecurity budgets are between 0% and 3% of their overall IT budget. Additionally, only 18 states have a cybersecurity budget line-item and only 16% of states reported a budget increase of 10% or greater since 2018.
- The 2022 IC3 Report reveals that in 2022, BEC attacks generated a total of $2,742,354,049 in losses across sectors, an increase of $346 million from 2021, and $875 million from 2020.
- There are 1.7 million ransomware attacks every day, which means 19 ransomware attacks every second. Cybersecurity Ventures predicts that by 2031, ransomware will cost victims $265 billion annually, and it will attack a business, consumer or device every 2 seconds.
- Ransomware attacks on state and local governments last an average of 7.3 days. Down time alone generates an average loss of $64,645.
In addition to state and local governments, educational institutions are also prime targets and victims of cyber attacks. In 2022, ransomware impacted nearly double the amount of universities and colleges than it did in 2021. Moody’s, which began tracking school districts in 2018, reports that the rates at which school districts are targeted has increased “exponentially”.
“Despite the many statistics and reports that detail the devastating losses caused from ransomware, business email compromise and other cyber attacks, many municipalities still find themselves underprepared for these threats,” said Stu Sjouwerman, CEO, KnowBe4. “Regardless of budget or size, the best way for all industry sectors to defend themselves against the threat of cyber attacks is to educate employees with new-school security awareness training and learn to develop a healthy skepticism of messages from even known contacts. Major municipality targets such as local and state governments and education and healthcare institutions are the backbone of civil service and society. Trained employees are essential to support IT teams, strengthen security culture and create a human firewall as the last line of defense to protect industries across the board, especially the municipality sectors we rely on everyday.”
To download The Economic Impact of Cyber Attacks on Municipalities report, visit https://www.knowbe4.com/hubfs/Economic-Impact-of-Cyber-Attacks-on-Municipalities.pdf.
To download KnowBe4’s Ransomware Hostage Rescue Manual, visit https://info.knowbe4.com/ransomware-hostage-rescue-manual-0.
About KnowBe4
KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, is used by more than 56,000 organizations around the globe. Founded by IT and data security specialist Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud and other social engineering tactics through a new-school approach to awareness training on security. Kevin Mitnick, an internationally recognized cybersecurity specialist and KnowBe4's Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Tens of thousands of organizations rely on KnowBe4 to mobilize their end users as their last line of defense.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005253/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
